英国随机对照试验中常规记录数据与标准前瞻性数据收集方法的比较
该研究以SANAD II抗癫痫药物试验为案例,比较常规电子健康记录数据与病例报告表数据在识别合格受试者、基线和随访评估中的属性和一致性。结论认为常规记录数据目前尚不能替代标准数据收集用于癫痫试验。
要点
- 常规数据在20个变量中15个存在显著缺失,所有临床变量均缺失。
- 癫痫发作和不良事件等临床变量的一致性差,仅处方日期和资源使用一致性满意。
- 常规记录数据目前尚不能用于癫痫试验的受试者识别和临床结局评估。
核心结论
- 常规记录数据在癫痫试验中用于受试者识别和临床结局评估存在显著限制,尚不能替代标准病例报告表数据收集。
研究设计与样本
- 比较常规记录数据与病例报告表数据在识别合格受试者、基线和随访评估中的属性和一致性,分类数据用Cohen's kappa评估,连续数据用Bland-Altman图评估。
主要发现
- 20个评估变量中15个存在显著缺失数据,包括所有临床变量。
- 大多数比较一致性差,包括癫痫发作和不良事件评估。
- 仅23/62(37%)参与者的首次癫痫发作日期在常规数据集中被识别。
- 抗癫痫药物处方日期和医疗资源使用事件的一致性满意。
临床怎么用
- 在癫痫及其他慢性病试验中,常规记录数据目前不宜用于受试者识别和临床结局评估,需进一步研究其属性、一致性、额外收益和成本效益。
局限性
- 常规记录数据存在显著缺失,尤其临床变量缺失严重,影响数据可用性。
- 多数临床变量一致性差,常规数据与病例报告表数据 agreement 不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Routinely recorded data held in electronic health records can be used to inform the conduct of randomised controlled trials (RCTs). However, limitations with access and accuracy have been identified. OBJECTIVE: Using epilepsy as an exemplar condition, we assessed the attributes and agreement of routinely recorded data compared to data collected using case report forms in a UK RCT assessing antiepileptic drug treatments for individuals newly diagnosed with epilepsy. METHODS: The case study RCT is the Standard and New Antiepileptic Drugs II (SANAD II) trial, a pragmatic, UK multicentre RCT assessing the clinical and cost-effectiveness of antiepileptic drugs as treatments for epilepsy. Ninety-eight of 470 eligible participants provided consent for access to routinely recorded secondary care data that were retrieved from NHS Digital Hospital Episode Statistics (N=71) and primary and secondary care data from The Secure Anonymised Information Linkage Databank (N=27). We assessed data items relevant to the identification of individuals eligible for inclusion in SANAD II, baseline and follow-up visits. The attributes of routinely recorded data were assessed including the degree of missing data. The agreement between routinely recorded data and data collected on case report forms in SANAD II was assessed using calculation of Cohen's kappa for categorical data and construction of Bland-Altman plots for continuous data. RESULTS: There was a significant degree of missing data in the routine record for 15 of the 20 variables assessed, including all clinical variables. Agreement was poor for the majority of comparisons, including the assessments of seizure occurrence and adverse events. For example, only 23/62 (37%) participants had a date of first-ever seizure identified in routine datasets. Agreement was satisfactory for the date of prescription of antiepileptic drugs and episodes of healthcare resource use. CONCLUSIONS: There are currently significant limitations preventing the use of routinely recorded data for participant identification and assessment of clinical outcomes in epilepsy, and potentially other chronic conditions. Further research is urgently required to assess the attributes, agreement, additional benefits, cost-effectiveness and 'optimal mix' of routinely recorded data compared to data collected using standard methods such as case report forms at clinic visits for people with epilepsy. TRIAL REGISTRATION: Standard and New Antiepileptic Drugs II (SANAD II (EudraCT No: 2012-001884-64, registered 05/09/2012; ISRCTN Number: ISRCTN30294119 , registered 03/07/2012)).
引用
- Powell GA, Bonnett LJ, Smith CT, et al. Using routinely recorded data in a UK RCT: a comparison to standard prospective data collection methods. Trials. 2021. PMID: 34225782. doi:10.1186/s13063-021-05294-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。